Loading
A phase 2 trial of Venetoclax in waldenström macroglobulinaemia, run by AbbVie, active and no longer recruiting.
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) is a phase 2 interventional study registered as NCT07387471 by AbbVie, with 14 participants planned, started 2026-03-17 and due to reach its primary completion in 2028-07. Interventions recorded: Venetoclax. Conditions listed: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Shares BCL-2 inhibitors, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/